ROSSARIBSEROSSARI BIOTECH LIMITEDMediumNeutral
Announced Sat, 18 Jul · 16:32 IST

Q1 FY27 results: revenue up 28%, PAT grows; ESOP grants and subsidiary transfer approved

Board & Shareholder Meetings View source PDF

ROSSARI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-3.4%1-day move
₹530.05
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-3.4-6.2-7.2-7.6-1.5
Up moveDown movePending
AI summary

Board approved Q1 FY27 results. Consolidated revenue rose to Rs 6,972 million (up 28.2% from Rs 5,437 million), PAT at Rs 350.95 million. Standalone revenue at Rs 4,822.75 million (up 31.9%), PAT at Rs 342.66 million. Also granted 4,000 ESOP options at Rs 531 each, allotted 2,500 shares. Approved transfer of Saudi arm RILC to Rossari Singapore for about Rs 24 crore to consolidate overseas holdings under one platform.

Likely market impact

Strong Q1 revenue growth. PAT growth modest. Subsidiary transfer is internal restructuring with no ownership change. Minor ESOP dilution.